Well-differentiated liposarcoma

Summary

Well-differentiated liposarcoma (MONDO:0005103) is a disease and 3 clinical trials. Top therapeutic interventions include betaine, palbociclib, and mirdametinib. A subtype of liposarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
• Phenotypes (HPO): 3
• Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.51	Europe	Validated

Signs & symptoms

Clinical features (HPO)

3 HPO clinical features (Orphanet curated; top 3 by frequency):

HPO ID	Term	Frequency
HP:0001482	Subcutaneous nodule	Very frequent (80-99%)
HP:0002579	Gastrointestinal dysmotility	Occasional (5-29%)
HP:0012211	Abnormal renal physiology	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	well-differentiated liposarcoma
Mondo ID	MONDO:0005103
EFO	EFO:0000736
Orphanet	99971
NCIT	C4250
UMLS	C1370889
MedGen	237164
GARD	0019721
Is cancer (heuristic)	no

Also known as: ALT · atypical lipoma · atypical lipomatous tumour · WDLS · well-differentiated liposarcoma

Data availability: 21 cell lines.

Disease family

This is a subtype of liposarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › lipomatous cancer › liposarcoma › well-differentiated liposarcoma

Related subtypes (18): liposarcoma of bone, adult liposarcoma, esophagus liposarcoma, pediatric liposarcoma, larynx liposarcoma, liposarcoma of the ovary, fibroblastic liposarcoma, kidney liposarcoma, gastric liposarcoma, breast liposarcoma, mixed liposarcoma, vulvar liposarcoma, cutaneous liposarcoma, mediastinum liposarcoma, intracranial liposarcoma, myxoid/round cell liposarcoma, pleomorphic liposarcoma, dedifferentiated liposarcoma

Subtypes (3): sclerosing liposarcoma, spindle cell liposarcoma, inflammatory liposarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06843967	PHASE1/PHASE2	RECRUITING	A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
NCT03073343	Not specified	RECRUITING	A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
NCT03740789	Not specified	UNKNOWN	Evaluation of Antiviral Indications on Chronic HBV Infection With Different Transaminase Levels

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BETAINE	4	1
PALBOCICLIB	4	1
MIRDAMETINIB	2	1
GLYCINEBETAINE	0	1